Liver Disease Therapeutic Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033
Description
Global Liver Disease Therapeutic Market Size
Liver Disease Therapeutic market is expected to reach US$ 31.53 billion by 2033 from US$ 15.04 billion in 2024, with a CAGR of 8.57% from 2025 to 2033. The market is being stimulated by the world's aging population, which is more vulnerable to liver disease and other chronic ailments.
Liver Disease Therapeutic Market Global Report by Therapy Type (Anti-Rejection Drugs/Immunosuppressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulins, Corticosteroids, Anti-Viral Drugs), Disease Type (Non-alcoholic Fatty Liver Disease (NAFLD), Viral Hepatitis (B, C, D), Alcoholic Liver Disease (ALD), Autoimmune Liver Disease (ALD)), End Users (Hospitals, Laboratories, Others), Countries and Company Analysis 2025-2033
Liver Disease Therapeutic Industry Overview
The illness of the liver Due to the rising incidence of liver-related conditions such cirrhosis, fatty liver disease, and hepatitis, the therapeutic sector is expanding significantly. Globally, these disorders are becoming more prevalent, especially as non-alcoholic fatty liver disease (NAFLD) rates rise due to changes in lifestyle, increased alcohol use, and obesity. Pharmaceutical companies are responding by creating novel treatments that focus on the root causes of liver illnesses, like new medications that cure liver fibrosis and antiviral therapy for hepatitis. Improved diagnostic methods and research advancements are speeding up the creation of innovative treatment alternatives that hold out hope for better patient outcomes and disease management.
Public health campaigns emphasizing the value of early identification and treatment of liver illnesses are another factor propelling the market. The need for efficient treatments keeps growing as healthcare systems around the world strive to enhance the detection and treatment of liver disease. Furthermore, new targets for therapeutic development are being found as a result of the increasing molecular understanding of liver diseases. However, the development and accessibility of medicines are complicated by issues like the high cost of therapy, regulatory barriers, and the complexity of liver illnesses. Notwithstanding these challenges, the market for liver disease treatments is anticipated to continue expanding due to continuous improvements in medical research and the expanding range of available treatments.
The high prevalence of liver diseases, the rise in alcohol usage, and poor eating habits are the primary factors that are anticipated to propel expansion in the market for liver disease therapies. For instance, according to a June 2021 study published in the Clinical Liver Disease journal, chronic liver disease (CLD) is one of the world's main causes of mortality and sickness, affecting over 1.5 billion people worldwide. Furthermore, according to a June 2021 published by the American Association for the Study of Liver Diseases, alcoholic liver disease (ALD) (2%), hepatitis B (29%), hepatitis C (9%), and non-alcoholic fatty liver disease (NAFLD) (59%), are the leading causes of prevalent disease. Furthermore, a study that was published in October 2022 in Clinical and Molecular Hepatology predicts that by 2040, the prevalence of nonalcoholic fatty liver disease (NAFLD) will be 55.7% worldwide. As a result, rising liver illnesses have contributed to the market's overall growth.
Growth Drivers for the Liver Disease Therapeutic Market
Growing Interest in Liver Transplants
The need for liver transplants is increasing as many people's liver disease progresses to end-stage liver failure. Thanks to technical developments including less invasive procedures and improved post-operative care, transplants are becoming more widely available. A liver transplant early recovery program (ERP) was introduced in Mumbai in May 2024 by Wockhardt Hospitals and the South Asian Liver Institute. The program's goal is to lower the cost of liver transplants by about 20–30%.
A greater emphasis on NAFLD (non-alcoholic fatty liver disease)
NAFLD is now the main focus of liver disease treatment due to the rise in obesity and diabetes. New drug treatments for the ailment and lifestyle modifications that can slow the progression of the disease are the main areas of ongoing study. The Indo-French Liver and Metabolic Disease Network (InFLiMeN), a virtual hub for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), was established by the Union Minister at the Institute of Liver and Biliary Sciences in New Delhi in July 2024.
Increasing Focus on Pharmaceutical Growth
The development of novel drugs to treat liver diseases is receiving a lot of funding from pharmaceutical corporations. This trend is being driven, especially in disease-prone nations, by the rising prevalence of chronic liver illnesses and the lucrative market potential for innovative medications. For example, Zydus Lifesciences, a company based in India, stated in February 2024 that it aims to introduce its first new medication in the US by early 2026 in order to capitalize on the multibillion-dollar market for treating a particular kind of liver illness.
Challenges in the Liver Disease Therapeutic Market
Complexity of Liver Diseases
Hepatitis, cirrhosis, fatty liver disease, and liver cancer are just a few of the many illnesses that fall under the umbrella of liver diseases. Each of these conditions has its own origins, rates of progression, and symptoms. The intricacy of these illnesses makes it challenging to create a treatment that works for everyone. How these diseases develop and react to therapy depends on a number of factors, including lifestyle choices, genetics, and co-existing medical problems. For instance, although both alcoholic liver disease and non-alcoholic fatty liver disease (NAFLD) impact liver function, their treatment modalities may differ. Although this variability necessitates individualized treatment regimens, it also poses difficulties for drug development and research. One of the biggest challenges in hepatology is still creating treatments that address the root causes of these conditions while taking the needs of each patient into account.
Limited Treatment Options
Options for a number of serious illnesses, such as cirrhosis and liver cancer, are still restricted despite tremendous advancements in the treatment of liver diseases. Antiviral medications for hepatitis have transformed treatment, yet palliative care or symptom management are still key components of liver cancer and cirrhosis treatments. Although liver transplantation is a feasible option for certain individuals, the lack of available donors prevents it from being a common solution. There is no known cure for liver cancer, and therapies like immunotherapy and chemotherapy have had only patchy results. Therefore, treatments that can successfully address the underlying causes of liver disorders, stop their progression, and enhance long-term patient outcomes are desperately needed. The gaps that still need to be filled are highlighted by the absence of focused therapy for these illnesses.
Liver Disease Therapeutic Market Overview by Regions
By countries, the global Liver Disease Therapeutic market is divided into United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand, Brazil, Mexico, Argentina, South Africa, Saudi Arabia and UAE.
United States Liver Disease Therapeutic Market
The rising incidence of liver disorders such cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) is driving growth in the US liver disease therapeutic market. The incidence of liver-related disorders is increasing due to a growing aging population, changing lifestyles, and increased alcohol intake, which is fueling the need for novel treatments. Drug development breakthroughs, such as antiviral medicines for hepatitis and new therapeutics for liver cancer and cirrhosis, are driving the market. The United States has made large investments in hepatology and is a major center for clinical trials and research. The need for more potent treatments for chronic liver illnesses, late-stage diagnosis, and exorbitant treatment costs are still obstacles, though. Promising growth prospects are presented by ongoing developments in targeted medicines and personalized medicine.
United Kingdom Liver Disease Therapeutic Market
The rising incidence of liver disorders such cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) is driving growth in the UK liver disease therapeutic market. The need for efficient therapies is growing as a result of the increasing prevalence of these disorders, which is being caused by variables such as obesity, alcohol use, and an aging population. Patient outcomes are being improved by notable developments in liver disease treatments, especially for liver cancer and hepatitis C. Furthermore, hepatology innovation is encouraged by the UK's emphasis on medical research and development, which is backed by government programs. There are still issues with advanced liver illnesses, such as a lack of available therapies, expensive therapy, and delayed diagnosis. Targeted treatments, early detection programs, and ongoing research are the main factors propelling the market's expansion.
India Liver Disease Therapeutic Market
Because liver illnesses such cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) are becoming more common, the Indian liver disease therapeutic market is expanding significantly. The burden of liver disorders in the nation is rising as a result of poor diet, rising obesity rates, changing lifestyles, and increased alcohol intake. The development of novel therapies for cirrhosis and liver cancer, as well as improvements in pharmacological treatments, especially for hepatitis B and C, are also driving the market. Progress is hampered by issues like low awareness, late-stage diagnoses, and poor healthcare facilities in rural areas. Notwithstanding these obstacles, it is anticipated that the need for efficient liver disease treatments would increase due to government programs, funding for research, and expanding access to healthcare.
Saudi Arabia Liver Disease Therapeutic Market
The rising prevalence of liver disorders such cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) is propelling the Saudi Arabian liver disease therapeutic market's quick growth. The burden of liver-related diseases is increasing due to factors such rising obesity rates, poor diets, and excessive alcohol use. New treatments for liver fibrosis and cancer, as well as antiviral medications for hepatitis B and C, are among the developments in liver disease treatments that are driving the market. Even with advancements, problems including low awareness, delayed diagnosis, and geographical differences in access to healthcare still exist. However, Saudi Arabia's liver disease therapeutic market is anticipated to keep growing in the upcoming years due to rising healthcare investments, advancements in medical infrastructure, and an emphasis on public health initiatives.
Therapy Type – Market breakup in 7 viewpoints:
1. Anti-Rejection Drugs/Immunosuppressants
2. Chemotherapy Drugs
3. Targeted therapy
4. Vaccines
5. Immunoglobulins
6. Corticosteroids
7. Anti-Viral Drugs
Disease Type – Market breakup in 4 viewpoints:
1. Non-alcoholic Fatty Liver Disease (NAFLD)
2. Viral Hepatitis (B, C, D)
3. Alcoholic Liver Disease (ALD)
4. Autoimmune Liver Disease (ALD)
End Users – Market breakup in 3 viewpoints:
1. Hospitals
2. Laboratories
3. Others
Country – Market breakup in 25 viewpoints:
North America
• United States
• Canada
Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• the Netherlands
• Turkey
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand
Latin America
• Brazil
• Mexico
• Argentina
Middle East & Africa
• South Africa
• Saudi Arabia
• United Arab Emirates
All the Key players have been covered from 4 Viewpoints:
• Overview
• Recent Development & Strategies
• Product Portfolio & Product Launch in Last 1 Year
• Revenue
Company Analysis
1. Abbott Laboratories
2. Astellas Pharma Inc.
3. Bristol-Mayers Squibb
4. Gilead Sciences
5. GlaxoSmithKline Pharmaceuticals Ltd
6. F. Hoffmann-La Roche Ltd
7. Merck & Co. Inc
8. Novartis AG
9. Sanofi S.A
10. Pfizer Inc.
11. Takeda Pharmaceuticals
Key Questions Answered in Report:
1. How big is the Liver Disease Therapeutic industry?
The global Liver Disease Therapeutic market size was valued at US$ 15.04 billion in 2024 and is expected to reach US$ 31.53 billion in 2033.
2. What is the Liver Disease Therapeutic growth rate?
The global Liver Disease Therapeutic market is expected to expand at a compound annual growth rate (CAGR) of 8.57% from 2025 to 2033.
3. Who are the key players in Liver Disease Therapeutic industry?
Some key players operating in the Liver Disease Therapeutic market includes Abbott Laboratories, Astellas Pharma Inc., Bristol-Mayers Squibb, Gilead Sciences, GlaxoSmithKline Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceuticals.
4. What are the factors driving the Liver Disease Therapeutic industry?
The illness of the liver Rising liver disease prevalence worldwide, improvements in medical research, expanding public awareness, an aging population, better diagnostic technologies, and the creation of more specialized and efficient treatments are the main drivers of the therapeutic sector.
5. Which Region held the largest market share in the Liver Disease Therapeutic industry?
North America is expected to hold the largest market share in the industry.
6. What segments are covered in the Liver Disease Therapeutic Market report?
Therapy Type, Disease Type, End Users and Countries segment are covered in this report.
Liver Disease Therapeutic market is expected to reach US$ 31.53 billion by 2033 from US$ 15.04 billion in 2024, with a CAGR of 8.57% from 2025 to 2033. The market is being stimulated by the world's aging population, which is more vulnerable to liver disease and other chronic ailments.
Liver Disease Therapeutic Market Global Report by Therapy Type (Anti-Rejection Drugs/Immunosuppressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulins, Corticosteroids, Anti-Viral Drugs), Disease Type (Non-alcoholic Fatty Liver Disease (NAFLD), Viral Hepatitis (B, C, D), Alcoholic Liver Disease (ALD), Autoimmune Liver Disease (ALD)), End Users (Hospitals, Laboratories, Others), Countries and Company Analysis 2025-2033
Liver Disease Therapeutic Industry Overview
The illness of the liver Due to the rising incidence of liver-related conditions such cirrhosis, fatty liver disease, and hepatitis, the therapeutic sector is expanding significantly. Globally, these disorders are becoming more prevalent, especially as non-alcoholic fatty liver disease (NAFLD) rates rise due to changes in lifestyle, increased alcohol use, and obesity. Pharmaceutical companies are responding by creating novel treatments that focus on the root causes of liver illnesses, like new medications that cure liver fibrosis and antiviral therapy for hepatitis. Improved diagnostic methods and research advancements are speeding up the creation of innovative treatment alternatives that hold out hope for better patient outcomes and disease management.
Public health campaigns emphasizing the value of early identification and treatment of liver illnesses are another factor propelling the market. The need for efficient treatments keeps growing as healthcare systems around the world strive to enhance the detection and treatment of liver disease. Furthermore, new targets for therapeutic development are being found as a result of the increasing molecular understanding of liver diseases. However, the development and accessibility of medicines are complicated by issues like the high cost of therapy, regulatory barriers, and the complexity of liver illnesses. Notwithstanding these challenges, the market for liver disease treatments is anticipated to continue expanding due to continuous improvements in medical research and the expanding range of available treatments.
The high prevalence of liver diseases, the rise in alcohol usage, and poor eating habits are the primary factors that are anticipated to propel expansion in the market for liver disease therapies. For instance, according to a June 2021 study published in the Clinical Liver Disease journal, chronic liver disease (CLD) is one of the world's main causes of mortality and sickness, affecting over 1.5 billion people worldwide. Furthermore, according to a June 2021 published by the American Association for the Study of Liver Diseases, alcoholic liver disease (ALD) (2%), hepatitis B (29%), hepatitis C (9%), and non-alcoholic fatty liver disease (NAFLD) (59%), are the leading causes of prevalent disease. Furthermore, a study that was published in October 2022 in Clinical and Molecular Hepatology predicts that by 2040, the prevalence of nonalcoholic fatty liver disease (NAFLD) will be 55.7% worldwide. As a result, rising liver illnesses have contributed to the market's overall growth.
Growth Drivers for the Liver Disease Therapeutic Market
Growing Interest in Liver Transplants
The need for liver transplants is increasing as many people's liver disease progresses to end-stage liver failure. Thanks to technical developments including less invasive procedures and improved post-operative care, transplants are becoming more widely available. A liver transplant early recovery program (ERP) was introduced in Mumbai in May 2024 by Wockhardt Hospitals and the South Asian Liver Institute. The program's goal is to lower the cost of liver transplants by about 20–30%.
A greater emphasis on NAFLD (non-alcoholic fatty liver disease)
NAFLD is now the main focus of liver disease treatment due to the rise in obesity and diabetes. New drug treatments for the ailment and lifestyle modifications that can slow the progression of the disease are the main areas of ongoing study. The Indo-French Liver and Metabolic Disease Network (InFLiMeN), a virtual hub for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), was established by the Union Minister at the Institute of Liver and Biliary Sciences in New Delhi in July 2024.
Increasing Focus on Pharmaceutical Growth
The development of novel drugs to treat liver diseases is receiving a lot of funding from pharmaceutical corporations. This trend is being driven, especially in disease-prone nations, by the rising prevalence of chronic liver illnesses and the lucrative market potential for innovative medications. For example, Zydus Lifesciences, a company based in India, stated in February 2024 that it aims to introduce its first new medication in the US by early 2026 in order to capitalize on the multibillion-dollar market for treating a particular kind of liver illness.
Challenges in the Liver Disease Therapeutic Market
Complexity of Liver Diseases
Hepatitis, cirrhosis, fatty liver disease, and liver cancer are just a few of the many illnesses that fall under the umbrella of liver diseases. Each of these conditions has its own origins, rates of progression, and symptoms. The intricacy of these illnesses makes it challenging to create a treatment that works for everyone. How these diseases develop and react to therapy depends on a number of factors, including lifestyle choices, genetics, and co-existing medical problems. For instance, although both alcoholic liver disease and non-alcoholic fatty liver disease (NAFLD) impact liver function, their treatment modalities may differ. Although this variability necessitates individualized treatment regimens, it also poses difficulties for drug development and research. One of the biggest challenges in hepatology is still creating treatments that address the root causes of these conditions while taking the needs of each patient into account.
Limited Treatment Options
Options for a number of serious illnesses, such as cirrhosis and liver cancer, are still restricted despite tremendous advancements in the treatment of liver diseases. Antiviral medications for hepatitis have transformed treatment, yet palliative care or symptom management are still key components of liver cancer and cirrhosis treatments. Although liver transplantation is a feasible option for certain individuals, the lack of available donors prevents it from being a common solution. There is no known cure for liver cancer, and therapies like immunotherapy and chemotherapy have had only patchy results. Therefore, treatments that can successfully address the underlying causes of liver disorders, stop their progression, and enhance long-term patient outcomes are desperately needed. The gaps that still need to be filled are highlighted by the absence of focused therapy for these illnesses.
Liver Disease Therapeutic Market Overview by Regions
By countries, the global Liver Disease Therapeutic market is divided into United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand, Brazil, Mexico, Argentina, South Africa, Saudi Arabia and UAE.
United States Liver Disease Therapeutic Market
The rising incidence of liver disorders such cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) is driving growth in the US liver disease therapeutic market. The incidence of liver-related disorders is increasing due to a growing aging population, changing lifestyles, and increased alcohol intake, which is fueling the need for novel treatments. Drug development breakthroughs, such as antiviral medicines for hepatitis and new therapeutics for liver cancer and cirrhosis, are driving the market. The United States has made large investments in hepatology and is a major center for clinical trials and research. The need for more potent treatments for chronic liver illnesses, late-stage diagnosis, and exorbitant treatment costs are still obstacles, though. Promising growth prospects are presented by ongoing developments in targeted medicines and personalized medicine.
United Kingdom Liver Disease Therapeutic Market
The rising incidence of liver disorders such cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) is driving growth in the UK liver disease therapeutic market. The need for efficient therapies is growing as a result of the increasing prevalence of these disorders, which is being caused by variables such as obesity, alcohol use, and an aging population. Patient outcomes are being improved by notable developments in liver disease treatments, especially for liver cancer and hepatitis C. Furthermore, hepatology innovation is encouraged by the UK's emphasis on medical research and development, which is backed by government programs. There are still issues with advanced liver illnesses, such as a lack of available therapies, expensive therapy, and delayed diagnosis. Targeted treatments, early detection programs, and ongoing research are the main factors propelling the market's expansion.
India Liver Disease Therapeutic Market
Because liver illnesses such cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) are becoming more common, the Indian liver disease therapeutic market is expanding significantly. The burden of liver disorders in the nation is rising as a result of poor diet, rising obesity rates, changing lifestyles, and increased alcohol intake. The development of novel therapies for cirrhosis and liver cancer, as well as improvements in pharmacological treatments, especially for hepatitis B and C, are also driving the market. Progress is hampered by issues like low awareness, late-stage diagnoses, and poor healthcare facilities in rural areas. Notwithstanding these obstacles, it is anticipated that the need for efficient liver disease treatments would increase due to government programs, funding for research, and expanding access to healthcare.
Saudi Arabia Liver Disease Therapeutic Market
The rising prevalence of liver disorders such cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD) is propelling the Saudi Arabian liver disease therapeutic market's quick growth. The burden of liver-related diseases is increasing due to factors such rising obesity rates, poor diets, and excessive alcohol use. New treatments for liver fibrosis and cancer, as well as antiviral medications for hepatitis B and C, are among the developments in liver disease treatments that are driving the market. Even with advancements, problems including low awareness, delayed diagnosis, and geographical differences in access to healthcare still exist. However, Saudi Arabia's liver disease therapeutic market is anticipated to keep growing in the upcoming years due to rising healthcare investments, advancements in medical infrastructure, and an emphasis on public health initiatives.
Therapy Type – Market breakup in 7 viewpoints:
1. Anti-Rejection Drugs/Immunosuppressants
2. Chemotherapy Drugs
3. Targeted therapy
4. Vaccines
5. Immunoglobulins
6. Corticosteroids
7. Anti-Viral Drugs
Disease Type – Market breakup in 4 viewpoints:
1. Non-alcoholic Fatty Liver Disease (NAFLD)
2. Viral Hepatitis (B, C, D)
3. Alcoholic Liver Disease (ALD)
4. Autoimmune Liver Disease (ALD)
End Users – Market breakup in 3 viewpoints:
1. Hospitals
2. Laboratories
3. Others
Country – Market breakup in 25 viewpoints:
North America
• United States
• Canada
Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• the Netherlands
• Turkey
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand
Latin America
• Brazil
• Mexico
• Argentina
Middle East & Africa
• South Africa
• Saudi Arabia
• United Arab Emirates
All the Key players have been covered from 4 Viewpoints:
• Overview
• Recent Development & Strategies
• Product Portfolio & Product Launch in Last 1 Year
• Revenue
Company Analysis
1. Abbott Laboratories
2. Astellas Pharma Inc.
3. Bristol-Mayers Squibb
4. Gilead Sciences
5. GlaxoSmithKline Pharmaceuticals Ltd
6. F. Hoffmann-La Roche Ltd
7. Merck & Co. Inc
8. Novartis AG
9. Sanofi S.A
10. Pfizer Inc.
11. Takeda Pharmaceuticals
Key Questions Answered in Report:
1. How big is the Liver Disease Therapeutic industry?
The global Liver Disease Therapeutic market size was valued at US$ 15.04 billion in 2024 and is expected to reach US$ 31.53 billion in 2033.
2. What is the Liver Disease Therapeutic growth rate?
The global Liver Disease Therapeutic market is expected to expand at a compound annual growth rate (CAGR) of 8.57% from 2025 to 2033.
3. Who are the key players in Liver Disease Therapeutic industry?
Some key players operating in the Liver Disease Therapeutic market includes Abbott Laboratories, Astellas Pharma Inc., Bristol-Mayers Squibb, Gilead Sciences, GlaxoSmithKline Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceuticals.
4. What are the factors driving the Liver Disease Therapeutic industry?
The illness of the liver Rising liver disease prevalence worldwide, improvements in medical research, expanding public awareness, an aging population, better diagnostic technologies, and the creation of more specialized and efficient treatments are the main drivers of the therapeutic sector.
5. Which Region held the largest market share in the Liver Disease Therapeutic industry?
North America is expected to hold the largest market share in the industry.
6. What segments are covered in the Liver Disease Therapeutic Market report?
Therapy Type, Disease Type, End Users and Countries segment are covered in this report.
Table of Contents
200 Pages
- 1. Introduction
- 2. Research & Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. Global Liver Disease Therapeutic Market
- 6. Market Share Analysis
- 6.1 Therapy Type
- 6.2 Disease Type
- 6.3 End Users
- 6.4 Country
- 7. Therapy Type
- 7.1 Anti-Rejection Drugs/Immunosuppressants
- 7.2 Chemotherapy Drugs
- 7.3 Targeted therapy
- 7.4 Vaccines
- 7.5 Immunoglobulins
- 7.6 Corticosteroids
- 7.7 Anti-Viral Drugs
- 8. Disease Type
- 8.1 Non-alcoholic Fatty Liver Disease (NAFLD)
- 8.2 Viral Hepatitis (B, C, D)
- 8.3 Alcoholic Liver Disease (ALD)
- 8.4 Autoimmune Liver Disease (ALD)
- 9. End Users
- 9.1 Hospitals
- 9.2 Laboratories
- 9.3 Others
- 10. Country
- 10.1 North America
- 10.1.1 United States
- 10.1.2 Canada
- 10.2 Europe
- 10.2.1 France
- 10.2.2 Germany
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Belgium
- 10.2.7 Netherlands
- 10.2.8 Turkey
- 10.3 Asia Pacific
- 10.3.1 China
- 10.3.2 Japan
- 10.3.3 India
- 10.3.4 Australia
- 10.3.5 South Korea
- 10.3.6 Thailand
- 10.3.7 Malaysia
- 10.3.8 Indonesia
- 10.3.9 New Zealand
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.2 Mexico
- 10.4.3 Argentina
- 10.5 Middle East & Africa
- 10.5.1 South Africa
- 10.5.2 Saudi Arabia
- 10.5.3 UAE
- 11. Porter’s Five Analysis
- 11.1 Bargaining Power of Buyers
- 11.2 Bargaining Power of Suppliers
- 11.3 Degree of Rivalry
- 11.4 Threat of New Entrants
- 11.5 Threat of Substitutes
- 12. SWOT Analysis
- 12.1 Strength
- 12.2 Weakness
- 12.3 Opportunity
- 12.4 Threat
- 13. Market Outlook and Opportunities
- 13.1 Emerging Technologies
- 13.2 Future Market Trends
- 13.3 Investment Opportunities
- 14. Company Analysis
- 14.1 Abbott Laboratories
- 14.1.1 Overview
- 14.1.2 Key persons
- 14.1.3 Recent Development & Strategies
- 14.1.4 Product Portfolio & Product Launch in Last 1 Year
- 14.1.5 Revenue
- 14.2 Astellas Pharma Inc.
- 14.2.1 Overview
- 14.2.2 Key persons
- 14.2.3 Recent Development & Strategies
- 14.2.4 Product Portfolio & Product Launch in Last 1 Year
- 14.2.5 Revenue
- 14.3 Bristol-Mayers Squibb
- 14.3.1 Overview
- 14.3.2 Key persons
- 14.3.3 Recent Development & Strategies
- 14.3.4 Product Portfolio & Product Launch in Last 1 Year
- 14.3.5 Revenue
- 14.4 Gilead Sciences
- 14.4.1 Overview
- 14.4.2 Key persons
- 14.4.3 Recent Development & Strategies
- 14.4.4 Product Portfolio & Product Launch in Last 1 Year
- 14.4.5 Revenue
- 14.5 GlaxoSmithKline Pharmaceuticals Ltd
- 14.5.1 Overview
- 14.5.2 Key persons
- 14.5.3 Recent Development & Strategies
- 14.5.4 Product Portfolio & Product Launch in Last 1 Year
- 14.5.5 Revenue
- 14.6 F. Hoffmann-La Roche Ltd
- 14.6.1 Overview
- 14.6.2 Key persons
- 14.6.3 Recent Development & Strategies
- 14.6.4 Product Portfolio & Product Launch in Last 1 Year
- 14.6.5 Revenue
- 14.7 Merck & Co. Inc
- 14.7.1 Overview
- 14.7.2 Key persons
- 14.7.3 Recent Development & Strategies
- 14.7.4 Product Portfolio & Product Launch in Last 1 Year
- 14.7.5 Revenue
- 14.8 Novartis AG
- 14.8.1 Overview
- 14.8.2 Key persons
- 14.8.3 Recent Development & Strategies
- 14.8.4 Product Portfolio & Product Launch in Last 1 Year
- 14.8.5 Revenue
- 14.9 Sanofi S.A
- 14.9.1 Overview
- 14.9.2 Key persons
- 14.9.3 Recent Development & Strategies
- 14.9.4 Product Portfolio & Product Launch in Last 1 Year
- 14.9.5 Revenue
- 14.10 Pfizer Inc.
- 14.10.1 Overview
- 14.10.2 Key persons
- 14.10.3 Recent Development & Strategies
- 14.10.4 Product Portfolio & Product Launch in Last 1 Year
- 14.10.5 Revenue
- 14.11 Takeda Pharmaceuticals
- 14.11.1 Overview
- 14.11.2 Key persons
- 14.11.3 Recent Development & Strategies
- 14.11.4 Product Portfolio & Product Launch in Last 1 Year
- 14.11.5 Revenue
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
